Prosthetic heart valve market anticipates continued steady growth

Sarah Sipek | | Cardiovascular Business | Interventional Cardiology

The U.S. prosthetic heart valve market is expected to reach $6.3 billion by the end of 2016, according to a new report from Future Market insights, a New York-based market intelligence and consulting firm.

According to the firm’s findings, an increased prevalence of valvular heart disease (VHD) is a leading cause of the market growth. Regulatory approval for heart valves, integration of technological advancements and an increasing number of heart valve implantation procedures are other factors expected to influence revenue growth of the global prosthetic heart valve market in the next 10 years.

Hospital usage accounted for 75 percent market share of the global prosthetic heart valve market in 2015. Rising demand for quicker treatment options and remedies is expected to promote the revenue growth of this segment over the 10-year forecast period.

However, some factors have the potential to limit market growth. The high cost of transcatheter heart valves, the resulting procedure risks and complications and product recalls could hinder the overall growth potential of the prosthetic heart valve market.

Edwards Lifesciences Corporation, St. Jude Medical, Medtronic, Boston Scientific, Abbott Laboratories, SYMETIS, LivaNova, CryoLife, Braile Biomedica, Colibri Heart Valve and JenaValve Technology remain leading players in the valve replacement space, according to the report. 

Sarah Sipek

Related Content

Cardiologists reflect on developing primary PCI in face of criticism and pushback
How TAVR valve choice impacts outcomes when treating type 1 bicuspid AS
IVUS-guided PCI reduces risks in patients with diabetes
Medtronic using AI to identify more TAVR patients in need
SAVR linked to higher 10-year survival rate than TAVR for low-risk patients
LAAC with Watchman FLX reduces bleeding risks after AFib ablation

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."